NEW YORK (GenomeWeb News) – Juvaris BioTherapeutics will use Antigen Discovery's high-throughput protein microarray screening system to discover disease-specific antigens for use in vaccines, Juvaris said today.
Antigen Discovery will retain rights to diagnostics related to the antigens.
Burlingame, Calif.-based Juvaris said that it will sponsor research for multiple disease targets and pay Antigen Discovery upfront payments. Juvaris will select optimal antigens from Antigen Discovery's efforts to combine with its own adjuvant technology to create highly immunogenic prophylactic and therapeutic vaccines against major unmet medical needs, it said.
Further terms of the alliance were not disclosed.